UBX Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Unity Biotechnology's net margin of 10.05%. Unity Biotechnology's return on equity of -- beat Electromed's return on equity of 15.62%.

Unity Biotechnology has a consensus price target of $7.00, signalling upside risk potential of 446.88%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 7.53%. Given that Unity Biotechnology has higher upside potential than Electromed, analysts believe Unity Biotechnology is more attractive than Electromed.

Unity Biotechnology has a beta of 0.804, which suggesting that the stock is 19.579% less volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Unity Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Unity Biotechnology pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Unity Biotechnology quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. Unity Biotechnology's net income of -$6.5M is lower than Electromed's net income of $1.5M. Notably, Unity Biotechnology's price-to-earnings ratio is -- while Electromed's PE ratio is 42.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Unity Biotechnology is -- versus 4.80x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Unity Biotechnology's net margin of -10.5%. Unity Biotechnology's return on equity of -- beat Myomo's return on equity of -84.04%.

Unity Biotechnology has a consensus price target of $7.00, signalling upside risk potential of 446.88%. On the other hand Myomo has an analysts' consensus of -- which suggests that it could grow by 16.34%. Given that Unity Biotechnology has higher upside potential than Myomo, analysts believe Unity Biotechnology is more attractive than Myomo.

Unity Biotechnology has a beta of 0.804, which suggesting that the stock is 19.579% less volatile than S&P 500. In comparison Myomo has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.909%.

Unity Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Unity Biotechnology pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Unity Biotechnology quarterly revenues are --, which are smaller than Myomo quarterly revenues of $9.2M. Unity Biotechnology's net income of -$6.5M is lower than Myomo's net income of -$966.4K. Notably, Unity Biotechnology's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Unity Biotechnology is -- versus 9.63x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -- compared to Unity Biotechnology's net margin of -4291.67%. Unity Biotechnology's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

Unity Biotechnology has a consensus price target of $7.00, signalling upside risk potential of 446.88%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 277.36%. Given that Unity Biotechnology has higher upside potential than Catheter Precision, analysts believe Unity Biotechnology is more attractive than Catheter Precision.

Unity Biotechnology has a beta of 0.804, which suggesting that the stock is 19.579% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.184, suggesting its less volatile than the S&P 500 by 118.441%.

Unity Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Unity Biotechnology pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Unity Biotechnology quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Unity Biotechnology's net income of -$6.5M is lower than Catheter Precision's net income of -$4.1M. Notably, Unity Biotechnology's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Unity Biotechnology is -- versus 1.41x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Unity Biotechnology's net margin of -17.98%. Unity Biotechnology's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Unity Biotechnology has a consensus price target of $7.00, signalling upside risk potential of 446.88%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 326.95%. Given that Unity Biotechnology has higher upside potential than Xtant Medical Holdings, analysts believe Unity Biotechnology is more attractive than Xtant Medical Holdings.

Unity Biotechnology has a beta of 0.804, which suggesting that the stock is 19.579% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Unity Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Unity Biotechnology pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Unity Biotechnology quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Unity Biotechnology's net income of -$6.5M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Unity Biotechnology's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Unity Biotechnology is -- versus 0.61x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.